Getting a tuberculosis patient into care within thirty days of leaving

Tuberculosis treatment takes months. **Patients who relocate internationally
partway through face real difficulty completing it**: a new country, a
different health system, and no thread connecting the clinic they left to the
one they arrive at.

The CDC's CureTB programme is that thread. It **links patients diagnosed
with TB disease to care at their destination**, within the United States or
abroad.

What it achieves

During 2016–2023, among 1,741 patients with a confirmed TB diagnosis
referred by CureTB:

The thirty days

That second figure is the finding. **Patients who started care within a month
of leaving completed treatment 91% of the time** — against 79% overall.

A gap in care is where TB treatment falls apart. Someone who arrives, settles,
and only then tries to find a clinic has weeks of interrupted treatment behind
them and a resistant infection potentially ahead. Someone whose next
appointment was arranged before they got on the plane simply continues.

**Timely initiation of care can facilitate continuity of care and support
completion of treatment** — which is the report's own conclusion, and the
reason the programme's work happens before departure rather than after.

Why it matters beyond the individual

Incomplete TB treatment is how drug-resistant tuberculosis is made. A patient
who takes half a course and stops has been given the worst of both outcomes:
still infected, and now with a strain selected for surviving the drugs.

**CureTB can serve as a model for public health strategies aimed at improving
outcomes for relocating patients** — a population that any disease programme
organised around a fixed address will otherwise lose.

*Source: Vera-Garcia C, Duran-Pena O, Ramirez M, et al. Continuity of Care for
Patients with Tuberculosis Relocating to Other Countries — CureTB Program,
2016–2023. MMWR, Centers for Disease Control and Prevention.*